Table 2.

Fetal parameters of rats administered KACY from GD6 to GD15.

	Groups (dose in mg/kg)
	Control	ASA 250	KACY 50	KACY 250	KACY 500	KACY 1000
Fetuses examined	178	87	180	186	179	176
Fetal weight (g)	2.32 ± 0.02	1.29 ± 0.02a	2.32 ± 0.01b,c	2.24 ± 0.01b,c	2.24 ± 0.02b,c	2.10 ± 0.01a,b
Fetal crown-rump length (cm)	2.94 ± 0.01	2.26 ± 0.02a,c	2.92 ± 0.01b,c	2.68 ± 0.01a,b,c	2.85 ± 0.01a,b,c	2.79 ± 0.01a,b
Placental weight (g)	0.54 ± 0.01	0.43 ± 0.01a	0.54 ± 0.01b,c	0.51 ± 0.01b,c	0.54 ± 0.01b,c	0.49 ± 0.01a,b
Placental diameter (cm)	1.33 ± 0.01	1.27 ± 0.02	1.31 ± 0.01	1.29 ± 0.01	1.34 ± 0.01	1.29 ± 0.03
Umbilical cord length (cm)	2.29 ± 0.02	1.30 ± 0.03a	2.32 ± 0.02b	1.85 ± 0.07a,b	2.24 ± 0.02a,b	2.08 ± 0.02a,b
Male/female fetuses	84/94	41/46	86/94	92/94	90/89	86/90
Sex ratio (male/female)	0.89	0.89	0.91	0.97	1.01	0.95

Evaluations of the fetuses from fifteen pregnant rats per group. ASA = acetylsalicylic acid; KACY = kramecyne. Significant difference (p < 0.05) in relation to the ^acontrol, ^bASA at 250 mg/kg and/or ^cKACY at 1000 mg/kg.